Medelis Publishes 'Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster'
Dr. Mike McGarry describes a nuanced preclinical process that can help a Chief Medical Officer (CMO) get into the clinic faster
Phoenix AZ — September 4, 2008 — Medelis, Inc., a contract research organization providing complete oncology clinical trial design, management and execution, today published a free new downloadable abstract, "Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster," an interview with Mike McGarry, Ph.D.
Dr. McGarry, VP of Preclinical Studies at Medelis, is a preclinical research scientist with 35 years of experience generating high quality animal-based data. In the interview, he describes a nuanced preclinical process that can help a Chief Medical Officer (CMO) get into the clinic faster. This approach hinges on a strategic, well-defined rodent model, quality data, and ongoing integration between the pre-clinical, regulatory and clinical teams.
Topics covered include:
- Critical factors for a CMO to understand and evaluate during this step in the drug development process
- Regulatory assessments and how to avoid hitting a preclinical wall
- The nuances and complexities of animal models, tumor selection, and other variables
- How to keep the preclinical, regulatory and clinical teams involved in feasibility dialogue
- The typical preclinical process and the questions a CMO should be asking at each step
- Additional requirements unique to oncology preclinical trials
- What to look for in an outside preclinical team.
For 30 years, Dr. McGarry served as an investigator and Director of the Department of Laboratory Animal Resources at the Roswell Park Cancer Institute working primarily in experimental hematology and immunology with basic scientists and clinical colleagues. He chaired the Institute’s Animal Care and Use Committee and served on the Scientific Review Committee of the Institute’s Human Studies Review Board.
Dr. McGarry served as an IACUC member at both the Mayo Foundation and Arizona State University. Whileserving on the IACUC he helped numerous colleagues write and execute research protocols in a variety of species for experimental therapeutics, toxicology, pharmaco-kinetics, photodynamic therapy, immuno- and radiation adjunct therapies, gene therapies, adoptive cell transfers and other leading edge technologies. He has himself worked with SCID-hu and nude immune deficient animals, many genetically altered (transgenic and knockout) and mutant mice in most common strains of mice. His experience extends to most other larger animal models routinely used in preclinical research.
The abstract is the third in Medelis' Peer Perspectives in Oncology Q&A series, which brings together respected researchers to discuss issues that face Chief Medical Officers today: rising costs, optimum patient accrual, targeted therapeutics, patient safety, FDA regulations, efficacy, budgets, and timelines.
The abstract is available for download at http://www.medelis.com/oncology_abstracts.html.
About Medelis, Inc.
Medelis, Inc. is an oncology contract research organization providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, team physicians and clinical trial management physicians, including Dan Von Hoff, James Gourzis and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Offerings include strategic plans for regulatory approval from phase I through final approval and complete worldwide oncology clinical trial design, management and execution.
Medelis is privately-held and located in Phoenix, Arizona with other U.S. locations in Nashville, Boston and Reno.